Omda AS, a leading provider of specialised software for healthcare and emergency response, today announced the acquisition of Dermicus AB, a telemedicine solutions company specialising in teledermatology and telewound care. Including Dermicus in Omda’s portfolio will further strengthen the group´s position in the market for medical imaging solutions.
Omda has entered into a binding agreement to acquire 100% of Dermicus AB. Completion of the transaction is subject to FDI filing and approval, which are expected to be obtained within 25 working days of signing.
The Dermicus platform provides specialised mobile applications and workflows designed for the remote diagnosis and management of skin conditions and chronic wounds. It enables the secure capture and remote review of patient images by specialists, streamlining the diagnostic process and enhancing accessibility to specialist care. In NHS regions in the UK, Dermicus has reduced dermatology waiting times from 26 days to under one day by enabling rapid assessments and the prioritisation of high-risk individuals.
The solution integrates AI support for image quality control and Dermicus has ongoing development and research projects with healthcare providers for AI supported diagnostics.
The Dermicus platform is widely used by public and private healthcare providers, with Sweden as its core market. Key customers include Region Stockholm and Region Skåne. Outside Sweden, the company serves customers in Australia, Austria, and the United Kingdom. Dermicus has 9 employees and is based in Gothenburg and Stockholm, Sweden.
With the acquisition of Dermicus, Omda extends its product offering in the medical imaging domain. Omda is a leading provider of imaging solutions in the Nordics, offering secure, end-to-end systems for managing medical images. The solutions are trusted by healthcare providers of all sizes, from small clinics to extensive regional and national imaging networks.
Sverre Flatby, Chief Executive Officer of Omda, sees opportunities for further growth by including Dermicus in Omda’s portfolio: “Dermicus has proven to connect hospitals, primary care and other professionals in the care value chain facilitating efficient workflows and better outcomes for patients. The usability of the mobile interface and the specialised workflows for all user groups broadens the target group for solutions on this platform. The solution complements our existing solutions in medical imaging and introduces a new way to use AI which will enhance other products in the portfolio and ultimately benefit our customers.”
Daniel Eliasson, Dermicus CEO also emphasises the synergies and growth opportunities: “Joining a large, international group like Omda will allow us to expand our footprint both in current markets and internationally. Our solutions are highly configurable and designed to integrate easily with the many systems across the care ecosystem. We aim to add value quickly for new user groups that already benefit from Omda’s solutions and to explore how our experience with mobile imaging and AI can have wider applications in other specialised healthcare fields.”
Acquisition details:
- Signing took place on December 20, 2024.
- Dermicus has budgeted sales for 2025 of 14 MSEK and positive EBITDAC (management forecast).
- The agreed transaction price is 19 MSEK and will be settled in two tranches; 12 MSEK at closing and 7 MSEK as a seller credit to be settled no later than 3Q-2027.
- Contingent upon reaching specific Sales and EBITDAC targets for the years 2025 and 2026, and additional Earn Out payment up to 15 MSEK will apply. The Earn Out will be paid out no later than 3Q-2027.
- Haavind and RSM have acted as advisors on legal and financial matters.
About Dermicus
Dermicus AB, formerly known as Gnosco, is a digital health company that helps its clients transform the diagnosis and treatment of skin conditions with solutions for teledermatology, telewound care and skin imaging. The company’s mission is to help healthcare providers re-engineer the diagnostic and treatment processes of skin conditions with purpose-built technology and proven implementation methods. The Dermicus platform is flexible and built to be configured to different care settings including hospitals, dermatology practices, primary care centres, pharmacies, nursing homes, visiting nursing. Dermicus is ISO 27001 certified for information security management, and ISO 13485 certified for medical device quality management.
For more information, visit www.dermicus.com
For further information concerning the acquisition please contact:
Einar Bonnevie
Chief Financial Officer, Omda AS
+47 91 55 45 32
einar.bonnevie@omda.com
Follow Omda on LinkedIn
Subscribe to our newsletter: http://eepurl.com/dsoOJH
